Fresenius Medical Care AG (NYSE:FMS) Short Interest Update

Fresenius Medical Care AG (NYSE:FMS) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 808,800 shares, a decline of 5.1% from the November 30th total of 852,500 shares. Based on an average trading volume of 272,600 shares, the short-interest ratio is presently 3.0 days.

Analysts Set New Price Targets

FMS has been the subject of a number of recent research reports. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Thursday, November 28th. They issued a “strong-buy” rating on the stock. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company. Finally, Truist Financial lifted their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Fresenius Medical Care has an average rating of “Hold” and a consensus target price of $24.30.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $22.64 on Thursday. The firm’s 50-day simple moving average is $22.19 and its 200 day simple moving average is $20.63. The stock has a market cap of $13.29 billion, a P/E ratio of 18.71, a P/E/G ratio of 0.96 and a beta of 0.93. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $24.31.

Institutional Trading of Fresenius Medical Care

A number of institutional investors have recently made changes to their positions in the stock. Wulff Hansen & CO. raised its holdings in Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Moran Wealth Management LLC lifted its holdings in shares of Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after buying an additional 74,621 shares during the period. Quantinno Capital Management LP boosted its stake in Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after buying an additional 48,554 shares in the last quarter. Triasima Portfolio Management inc. grew its holdings in Fresenius Medical Care by 27.4% during the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after acquiring an additional 18,360 shares during the period. Finally, Franklin Resources Inc. raised its position in Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after acquiring an additional 2,386 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.